Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome [Case Report]

Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome Skip to main page content

HOME CURRENT ISSUE PAST ISSUES SUPPLEMENTS REPRINTS ALERTS KEYWORDS GO Advanced Search ? Advertisement
Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome Alex Dinh, Ashok Anathasayanan and Lisa M. Rubin?

Alex Dinh, B.S., is Medical Extern, Department of Medicine and Biomedical Sciences, SUNY at Buffalo, Buffalo, NY. Ashok Anathasayanan, M.D., is Nephrology Fellow, Department of Nephrology; and Lisa M. Rubin, Pharm.D., is Clinical Pharmacy Specialist, Nephrology and Formulary Management, Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo. Address correspondence to Dr. Rubin (lisa.rubin{at}va.gov). Abstract Purpose A severe case of Shiga toxin Escherichia coli (STEC)-associated hemolytic uremic syndrome (HUS) successfully treated with eculizumab is reported.

Summary An 18-year-old man was admitted to the intensive care unit with HUS due to laboratory-confirmed STEC O121. He was initially treated with plasmapheresis and required hemodialysis for anuric acute kidney injury. Plasmapheresis was stopped due to complications. He continued to show evidence of ongoing hemolysis and kidney injury. Due to the lack of clinical improvement in renal function and hematologic status as well as the severity of the patient’s symptoms, the decision was made to initiate eculizumab. The patient was given i.v. eculizumab 900 mg infused over 35 minutes weekly for four weeks, followed by 1200 mg infused over 35 minutes one week later as the fifth dose and then every two weeks thereafter. The patient also received i.v. ciprofloxacin 400 mg infused over 60 minutes once every 24 hours for meningococcal prophylaxis and bacterial eradication. After initiation of eculizumab, the patient’s platelet count rapidly improved. After three doses of eculizumab, the patient’s renal function improved, and further hemodialysis was no longer required. The patient continued to receive twice-monthly eculizumab infusions to complete a two-month treatment course (seven doses), at which point his renal function returned to baseline. The initial two infusions were administered as an inpatient, and the remainder was infused in the outpatient setting.

Conclusion An 18-year-old man who developed severe HUS due to STEC O121 and was unresponsive to traditional supportive therapies was successfully treated with eculizumab.

Copyright ? 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved. CiteULike Delicious Digg Facebook Google+ Reddit Twitter What's this?

? Previous | Next Article ? Table of Contents This Article doi: 10.2146/ajhp140134 American Journal of Health-System Pharmacy January 15, 2015 vol. 72 no. 2 117-120 ? Abstract Full Text Full Text (PDF) Classifications Print Content Case Report Services Email this article to a colleague Alert me when this article is cited Alert me if a correction is posted Alert me when eLetters are published Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Download to citation manager eLetters Submit an eLetter No eLetters published Citing Articles Load citing article information Google Scholar Articles by Dinh, A. Articles by Rubin, L. M. PubMed PubMed citation Articles by Dinh, A. Articles by Rubin, L. M. Related Content Load related web page information Social Bookmarking CiteULike Delicious Digg Facebook Google+ Reddit Twitter What's this?

Current Issue February 15, 2015, 72 (4) Alert me to new issues of American Journal of Health-System Pharmacy From the Cover RhOD immune globulin products for prevention of alloimmunization during pregnancy Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective Comparative analytics of infusion pump data across multiple hospital systems ABOUT AJHP SUBSCRIPTIONS FOR AUTHORS/REVIEWERS PERMISSION REQUESTS ADVERTISING EMAIL ALERTS (FREE) RSS FEEDS (FREE) HELP CONTACT US/FEEDBACK American Society of Health System Pharmacists Learning Center (CE) Store Meetings & Conferences ASHP Foundation MOST READ ARTICLES (Last 30 Days) Clinical practice guidelines for antimicrobial prophylaxis in surgery Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists How to write a patient case report Treatment of poisoning caused by {beta}-adrenergic and calcium-channel blockers ? View all Most Read articles Advertisement ? 2015 by the American Society of Health-System Pharmacists. Terms of Use | Copyright Online ISSN: 1535-2900 Print ISSN: 1079-2082

View the original article here